ABVC Net Invested Capital vs Common Stock Analysis
ABVC Stock | USD 0.47 0.01 1.06% |
ABVC Biopharma financial indicator trend analysis is way more than just evaluating ABVC Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ABVC Biopharma is a good investment. Please check the relationship between ABVC Biopharma Net Invested Capital and its Common Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
Net Invested Capital vs Common Stock
Net Invested Capital vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ABVC Biopharma Net Invested Capital account and Common Stock. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between ABVC Biopharma's Net Invested Capital and Common Stock is -0.48. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Common Stock in the same time period over historical financial statements of ABVC Biopharma, assuming nothing else is changed. The correlation between historical values of ABVC Biopharma's Net Invested Capital and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of ABVC Biopharma are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Net Invested Capital i.e., ABVC Biopharma's Net Invested Capital and Common Stock go up and down completely randomly.
Correlation Coefficient | -0.48 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Common Stock
Most indicators from ABVC Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ABVC Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.As of December 11, 2024, Selling General Administrative is expected to decline to about 5 M. In addition to that, Tax Provision is expected to decline to about 217.9 K
2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 11.7M | 16.1M | 8.4M | 4.2M | Total Revenue | 355.8K | 969.8K | 152.4K | 157.4K |
ABVC Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
ABVC Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ABVC Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 6.9M | 11.6M | 13.7M | 9.9M | 14.5M | 15.2M | |
Short Long Term Debt Total | 4.6M | 6.5M | 3.1M | 3.1M | 2.3M | 1.9M | |
Total Current Liabilities | 6.8M | 4.8M | 3.7M | 5.8M | 5.9M | 6.2M | |
Total Stockholder Equity | (151.0K) | 3.4M | 8.8M | 3.1M | 8.4M | 8.8M | |
Net Debt | 4.4M | 2.2M | (2.7M) | 3.0M | 2.2M | 2.3M | |
Retained Earnings | (15.9M) | (25.6M) | (38.5M) | (54.9M) | (65.4M) | (62.1M) | |
Common Stock Shares Outstanding | 1.7M | 2.0M | 2.5M | 3.2M | 4.3M | 4.6M | |
Liabilities And Stockholders Equity | 6.9M | 11.6M | 13.7M | 9.9M | 14.5M | 15.2M | |
Non Current Liabilities Total | 238.4K | 4.1M | 1.1M | 420.2K | 429.1K | 407.7K | |
Inventory | (477.0K) | (839.7K) | 26.0K | 1.3M | 1.5M | 1.6M | |
Other Stockholder Equity | 15.0M | 28.5M | 46.8M | 57.5M | 73.3M | 76.9M | |
Total Liab | 7.1M | 8.9M | 4.8M | 6.2M | 6.4M | 6.7M | |
Total Current Assets | 878.2K | 6.2M | 9.6M | 3.0M | 1.7M | 1.4M | |
Short Term Debt | 4.3M | 2.4M | 2.0M | 2.3M | 1.9M | 1.3M | |
Other Current Liab | 2.4M | 2.4M | 1.7M | 3.3M | 3.9M | 4.1M | |
Cash | 144.3K | 4.3M | 5.8M | 85.3K | 60.2K | 57.1K | |
Cash And Short Term Investments | 144.3K | 4.3M | 5.9M | 161.1K | 139.5K | 132.5K | |
Common Stock | 19.5K | 24.4K | 28.9K | 32.9K | 7.9K | 7.5K | |
Net Receivables | 640.5K | 999.4K | 1.7M | 1.4M | 759.6K | 625.0K | |
Other Current Assets | 570.4K | 900.4K | 1.9M | 1.5M | 757.7K | 388.3K | |
Non Current Assets Total | 6.0M | 5.4M | 4.1M | 6.9M | 12.8M | 13.5M | |
Non Currrent Assets Other | 179.5K | 164.8K | 160.5K | 1.3M | 1.5M | 1.6M | |
Common Stock Total Equity | 213.7K | 213.9K | 19.5K | 24.4K | 28.1K | 26.7K | |
Accumulated Other Comprehensive Income | 663.8K | 564.9K | 539.7K | 517.1K | 516.4K | 396.8K | |
Net Tangible Assets | (5.7M) | (151.0K) | 3.4M | 8.8M | 10.2M | 10.7M | |
Other Assets | 1.4M | 1.6M | 2.0M | 1.1M | 1.3M | 1.4M | |
Short Long Term Debt | 4.0M | 2.1M | 1.8M | 1.9M | 1.5M | 2.0M | |
Other Liab | 27.5K | 2.9K | 19.3K | 10.6K | 12.2K | 11.0K | |
Short Term Investments | 3.4M | 1.2M | 108.1K | 75.8K | 79.3K | 75.3K | |
Long Term Investments | 3.4M | 1.2M | 932.8K | 842.1K | 2.5M | 1.8M | |
Property Plant Equipment | 510.1K | 1.0M | 2.3M | 2.0M | 2.3M | 2.4M | |
Net Invested Capital | 3.9M | 8.1M | 10.7M | 5.0M | 9.9M | 10.3M | |
Net Working Capital | (5.9M) | 1.3M | 5.9M | (2.8M) | (4.3M) | (4.1M) | |
Capital Stock | 19.5K | 24.4K | 28.9K | 32.9K | 7.9K | 7.5K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share 0.017 | Quarterly Revenue Growth 18.175 | Return On Assets (0.45) | Return On Equity (3.20) |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.